Reprogramming the immune system of cancer patients
Scientists at Jerusalem’s Hadassah hospital and Bar-Ilan University have developed HBI0101- a CAR-T therapy for multiple myeloma and amyloidosis, benefiting over 90% of patients in trials. Los Angeles-based Immix BioPharma will commercialize HBI0101.
This entry was posted in Israel's Medical Achievements
. Bookmark the permalink